

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/631,923	07/31/2003	Raya Levin	4517-4002	9017
27123	7590 01/18/2006		EXAM	INER
MORGAN & FINNEGAN, L.L.P. 3 WORLD FINANCIAL CENTER			LISH, PETER J	
	, NY 10281-2101		ART UNIT	PAPER NUMBER
	•		1754	

DATE MAILED: 01/18/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

-	Application No.	Applicant(s)				
	10/631,923	LEVIN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Peter J. Lish	1754				
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with th	e correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	PATE OF THIS COMMUNICAT 136(a). In no event, however, may a reply b will apply and will expire SIX (6) MONTHS f e, cause the application to become ABANDO	ION. e timely filed from the mailing date of this communication. DNED (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on 18 C	October 2005.					
3) Since this application is in condition for allowa	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11	, 453 O.G. 213.				
Disposition of Claims						
4) Claim(s) 1-26 is/are pending in the application 4a) Of the above claim(s) 1-22 and 26 is/are w 5) Claim(s) is/are allowed. 6) Claim(s) 23-25 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	rithdrawn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine 11.	cepted or b) objected to by the drawing(s) be held in abeyance.	See 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureat * See the attached detailed Office action for a list	ts have been received. ts have been received in Applic prity documents have been rece u (PCT Rule 17.2(a)).	cation No eived in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 7/8/04.	4) Interview Summ Paper No(s)/Ma 5) Notice of Inform 6) Other:					

DETAILED ACTION

Election/Restrictions

Claims 1-22 and 26 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 10/18/05.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 23 and 25 are rejected under 35 U.S.C. 102(b) as being anticipated by Gennaro (Remington: The Science and Practice of Pharmacy).

Gennaro teaches processes for the production of tablets. The process of wet granulation comprises mixing the tablet ingredients in a high shear mixer followed by drying in a flat bed oven, such as a fluidized bed oven (pages 1623-1624). No difference is seen between the process of Gennaro and that of the instantly claimed invention.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are

such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 24 is rejected under 35 U.S.C. 103(a) as being unpatentable over Gennaro as applied above and further in view of Chau et al. (US 5,637,313).

Gennaro does not specifically teach the use of calcium carbonate as an ingredient in the production of tablets. Chau et al., however, teaches that calcium carbonate is often included in a variety of tablets as antacids and bulking agents. It would have been obvious to one of ordinary skill at the time of invention to include calcium carbonate in a tablet (such as a vitamin or an antacid) produced by the process of Gennaro, as the use of calcium carbonate is a variety of medicines, vitamins, and supplements is known in the art.

Claim 24 is rejected under 35 U.S.C. 103(a) as being unpatentable over Gennaro as applied above and further in view of Iorio (US 4,812,303).

Gennaro does not specifically teach the use of calcium carbonate as an ingredient in the production of tablets. Iorio, however, teaches that calcium carbonate is used as an ingredient in the production of calcium supplement tablets. The tablets are made by conventional processes, such as those taught by Gennaro. It would have been obvious to one of ordinary skill at the time of invention to use the conventional tabletting processes of Gennaro to make the calcium supplements of Iorio.

Art Unit: 1754

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter J. Lish whose telephone number is 571-272-1354. The examiner can normally be reached on 9:00-6:00 Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Stanley Silverman can be reached on 571-272-1358. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

PL

STANKEY S. SILVERMAN SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1700